UBS AM
HARP

UBS AM’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

UBS AM’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-44,265
Closed -$9.26M – 2788
2021
Q1 		$9.26M Buy
+44,265
New +$8.87M ﹤0.01% 1111

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

UBS AM's HARP Position: Q2 2021 in Review

UBS AM sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q2 2021, closing a stake of 44,265 shares — an estimated $9.26M sold.

UBS AM first reported a position in HARP in Q1 2021 and held it in 1 quarter. The position peaked at $9.26M in Q1 2021. 85 funds tracked by Wall St. Rank hold HARP as of Q2 2021.

  • UBS AM reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • UBS AM sold 44,265 Harpoon Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $9.26M.
  • UBS AM first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • UBS AM's Harpoon Therapeutics, Inc. Common Stock position peaked at $9.26M in Q1 2021.
  • 85 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q2 2021.

Based on UBS AM's 13F filing for Q2 2021, filed 16 Aug 2021.